Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Celanese Presents Innovations in EVA Polymers at Targeting Ocular Disorders Conference

Celanese Corporation
Posted on: 15 Sep 16

Celanese Corporation (NYSE: CE), a global technology and specialty materials company, will present “Driving Ophthalmic Drug Delivery Innovation with EVA” on Tuesday, September 20 at the 2016 Targeting Ocular Disorders Conference in Boston, Mass.

“Celanese is working with its customers to develop state-of-the-art drug delivery systems using our pharmaceutical material solutions,” said Susan Rahe, global business director, Celanese EVA polymers business. “VitalDose® EVA polymers offer pharmaceutical companies flexibility in product design to supply excipients that can be formulated to meet demanding release criteria and regulatory requirements.”

“Our broad medical and pharmaceutical polymer portfolio is creating comfortable and easy-to-use drug delivery devices and implants,” said Kelsey Achenbach, strategic marketing manager for the Celanese EVA polymers business. “Improving patient care has led to recent innovations in our EVA polymer portfolio that are creating broader device and implant design options to meet changing drug delivery needs.”

During the presentation Achenbach will focus on how VitalDose® EVA polymers can be a solution in solving patient needs in ophthalmic drug delivery, mainly patient compliance, drug dosing and sustained drug release to various parts of the eye. The presentation will highlight the following Celanese product:

  • VitalDose® EVA – acontrolled-release excipient ideal for use in pharmaceutical drug delivery implants that require a consistent release of active ingredients. VitalDose® EVA polymers may be used alone or in combination with other excipients and/or additives to achieve desired release-rate profiles.

Celanese Presentation
Topic: “Driving Ophthalmic Drug Delivery Innovation with EVA”
Date: Tuesday, September 20, 2016
Time: 12:20 – 12:35 p.m. Eastern Time
Presenters: Kelsey Achenbach, Strategic Marketing Manager, Celanese EVA polymers business

A special discount code has been created to save on standard registration pricing. To take advantage of this promotion, reference promotion code DOTCOOP16 when registering for this conference.

For more information on Celanese’s medical and pharmaceutical solutions for medical technology applications, visit

About Celanese

Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our two complementary business cores, Acetyl Chain and Materials Solutions, use the full breadth of Celanese’s global chemistry, technology and business expertise to create value for our customers and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 7,000 employees worldwide and had 2015 net sales of $5.7 billion. For more information about Celanese and our product offerings, visit or our blog at .

All registered trademarks are owned by Celanese International Corporation or its affiliates.

Forward-Looking Statements

This release may contain “forward-looking statements,” which include information concerning the company’s plans, objectives, goals, strategies, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. When used in this release, the words “outlook,” “forecast,” “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the company or its customers will realize these benefits or that these expectations will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained in this release. Numerous factors, many of which are beyond the company’s control, could cause actual results to differ materially from those expressed as forward-looking statements. Other risk factors include those that are discussed in the company’s filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

View source version on

Business Wire

Last updated on: 15/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.